Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healthlead PCLBKK:HL -0.88%75 ROC (Joel Greenblatt) % is 16.73% as of Mar. 2026, which is 49% below its 10-year median of 32.74. GuruFocus rates BKK:HL with a GF Score™ of 75/100 and a GF Value™ of ฿11.06 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 669 Healthcare Providers & Services companies, Healthlead PCL ranks better than 57.4% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Healthlead PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 16.73%.
The historical rank and industry rank for Healthlead PCL's ROC (Joel Greenblatt) % or its related term are showing as below:
BKK:HL'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.9 Med: 32.74 Max: 48.14
Current: 16.9
During the past 7 years, Healthlead PCL's highest ROC (Joel Greenblatt) % was 48.14%. The lowest was 16.90%. And the median was 32.74%.
BKK:HL's ROC (Joel Greenblatt) % is ranked better than 57.4% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: 12.54
vs BKK:HL: 16.90
Healthlead PCL's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -21.70% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Healthlead PCL ROC (Joel Greenblatt) % Related Terms
Healthlead PCL ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Healthlead PCL's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Healthlead PCL's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthlead PCL ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Healthlead PCL's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 16.73% mean?
Healthlead PCL (BKK:HL) has a ROC (Joel Greenblatt) % of 16.73% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Healthlead PCL and its competitors. This is 49% below median its historical median of 32.74. Over the past decade, Healthlead PCL's ROC (Joel Greenblatt) % has ranged from 16.90 to 48.14. According to the industry distribution chart, Healthlead PCL ranks #285 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 42.6%.
Is Healthlead PCL's ROC (Joel Greenblatt) % too high?
Healthlead PCL's current ROC (Joel Greenblatt) % of 16.73% is 49% below median its 10-year median of 32.74. Over the past 10 years, this metric has ranged from a low of 16.90 to a high of 48.14. The Healthcare Providers & Services industry median ROC (Joel Greenblatt) % is 12.54. Healthlead PCL's value of 16.73% is 33.4% above this industry median. Based on the distribution chart, Healthlead PCL ranks #285 out of 669 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Healthlead PCL has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's ROC (Joel Greenblatt) % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Healthlead PCL ranks #285 out of 669 companies for ROC (Joel Greenblatt) %. This puts Healthlead PCL in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 12.54. Healthlead PCL's value of 16.73% is 33.4% above this benchmark. Historically, Healthlead PCL's own ROC (Joel Greenblatt) % has ranged from 16.90 to 48.14 over the past decade. While the company's 10-year median is 32.74 vs. the industry median of 12.54, Healthlead PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.54, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healthlead PCL's current ROC (Joel Greenblatt) % of 16.73% is 33.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Healthlead PCL and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthlead PCL's current ROC (Joel Greenblatt) % is 16.73%, which is 49% below median its own 10-year median of 32.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿11.06, compared to a current price of ฿5.60 — trading 49.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 16.73%, which is 49% below median its 10-year median of 32.74 and 33.4% above the Healthcare Providers & Services industry median of 12.54. Healthlead PCL's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current ROC (Joel Greenblatt) % is 16.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthlead PCL (BKK:HL) Overvalued in 2026?
Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued.
The current stock price of ฿5.60 is trading 49.4% below its estimated GF Value™ of ฿11.06.
GuruFocus considers Healthlead PCL to be Significantly Undervalued.
Key valuation signals for BKK:HL:
ROC (Joel Greenblatt) %: 16.73% (49% below median its 10-year median of 32.74)
GF Value™: ฿11.06 vs. price of ฿5.60 (49.4% below fair value)
Industry Position: 33.4% above the Healthcare Providers & Services median (#285 of 669)
No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
75GF Score
Get the complete analysis for BKK:HL
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:HL has been successfully added to your 
